Across the recent three months, 9 analysts have shared their insights on Intellia Therapeutics NTLA, expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 3 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $46.56, a high estimate of $88.00, and a low estimate of $18.00. A 17.96% drop is evident in the current average compared to the previous average price target of $56.75.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Intellia Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | Lowers | Outperform | $60.00 | $70.00 |
| Gena Wang | Barclays | Lowers | Overweight | $55.00 | $76.00 |
| David Lebowitz | Citigroup | Lowers | Neutral | $19.00 | $25.00 |
| Salveen Richter | Goldman Sachs | Lowers | Neutral | $20.00 | $31.00 |
| Jack Allen | Baird | Lowers | Neutral | $18.00 | $24.00 |
| Geulah Livshits | Chardan Capital | Lowers | Buy | $88.00 | $94.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $54.00 | $54.00 |
| Debanjana Chatterjee | Jones Trading | Announces | Buy | $41.00 | - |
| Dae Gon Ha | Stifel | Lowers | Buy | $64.00 | $80.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Intellia Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intellia Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Intellia Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Intellia Therapeutics faced challenges, resulting in a decline of approximately -24.02% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Intellia Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1489.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Intellia Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.04%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Intellia Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.48%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Intellia Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
